1[1]Lazarus JM,Bourgoignie JJ,Buckalew VM,et al.Achievement and safety of a low BP goal in chronic renal disease.The Modification of Diet in Renal Disease Study Group.Hypertension ,1997,29:641-650
2[2]KeaneWF,EknoyanG.Proteinuria.Albuminria,RiskAssessment.Detection,Elimination(PARADE):A position paper of the National Kidney Foundation.Am J Kidney Dis,1999,33:1004-1010
4[4]Tall MW,Brenner BM.Renalprotective benefits of RAS inhibition:from ACEI to agniotensin Ⅱ antagonists.Kidney Int,2000,57:1803
5[5]Belz GG.Breithaupt K,Erb K.Kleinbloesem CH.Wolf GK:Influence of the angiotensin converting enzyme inhibitor cilazapril.the beta-blocker propranolol and their combination on haemodynamics in hypertension.J Hypertens,1989,7:817-824
6[6]The Joint National Committee.The Sixth Report of the Joint National Committee on Prevention,Detection,Evaluation and Treatment of High Blood Pressure.Arch Intern Med,1997,157:2413-2446
7[7]Maschio G,Alberti D,Janin G,et al.Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency:the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Disease trial.N Engl J Med,1996,334:939-945
8[8]Toto RD.Renal insufficiency due to angiontensin-converting enzyme inhibitors.Miner Electrolyte Metab,1994,20:193-200
3LaZarus JU, Bourgoignie J J, Buekalew VM, et al, Achievement and safety of a low Bp goal in chronic renal disease,The Modification, of diet in renal disease study group Hypertension, 1997; 29 : 641 - 650.
4Keane WF, EknoyanG. Proteinuria, Albuminria, Risk Assessment,detection, Elimination(PARADE) :A position paper of the National kidney Foundation. Am J Kidney Dis, 1999; 33 : 1004 - 1010.
